CCWM
SPRB

Cassaday & Co Wealth Management’s Spruce Biosciences SPRB Stock Holding History

Cassaday & Co Wealth Management’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108 Hold
2
– – ﹤0.01% 1263
2026
Q1 		$130 Buy
+2
New +$138 ﹤0.01% 1312

Other funds holding SPRB

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return

Cassaday & Co Wealth Management's SPRB Position: Q2 2026 in Review

Cassaday & Co Wealth Management held its Spruce Biosciences (SPRB) position steady in Q2 2026 at 2 shares worth $108. The position accounts for ﹤0.01% of the portfolio, ranked #1263.

Cassaday & Co Wealth Management first reported a position in SPRB in Q1 2026 and has held it in 2 quarters since. The position peaked at $130 in Q1 2026. 57 funds tracked by Wall St. Rank hold SPRB as of Q2 2026.

  • Cassaday & Co Wealth Management held 2 shares of Spruce Biosciences worth $108 as of Q2 2026.
  • Cassaday & Co Wealth Management left its Spruce Biosciences share count unchanged in Q2 2026.
  • Spruce Biosciences made up ﹤0.01% of Cassaday & Co Wealth Management's portfolio in Q2 2026, its #1263 holding.
  • Cassaday & Co Wealth Management first reported a position in Spruce Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Cassaday & Co Wealth Management's Spruce Biosciences position peaked at $130 in Q1 2026.
  • 57 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.